Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Announces Earnings Results, Misses Expectations By $0.10 EPS

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.10), Zacks reports.

Lakewood-Amedex Biotherapeutics Price Performance

NASDAQ:LABT traded down $0.06 during trading hours on Monday, hitting $0.22. 828,332 shares of the stock were exchanged, compared to its average volume of 7,485,027. The company’s 50 day moving average is $0.99. Lakewood-Amedex Biotherapeutics has a twelve month low of $0.17 and a twelve month high of $98.20. The firm has a market capitalization of $519,978.00 and a P/E ratio of -0.05.

Analyst Upgrades and Downgrades

LABT has been the topic of a number of recent analyst reports. Wall Street Zen lowered Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 7th. Weiss Ratings upgraded Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. Finally, HC Wainwright initiated coverage on Lakewood-Amedex Biotherapeutics in a research note on Wednesday, October 28th. They issued a “buy” rating for the company. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold”.

Get Our Latest Stock Report on Lakewood-Amedex Biotherapeutics

About Lakewood-Amedex Biotherapeutics

(Get Free Report)

Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.

Featured Stories

Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.